Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma

Annals of Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2014, Pages 185-191

  Higuchi, Mitsunori ^a   Hasegawa, Takeo ^a   Osugi, Jun ^a   Suzuki, Hiroyuki ^a   Gotoh, Mitsukazu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

18F deoxyglucose positron emission tomography; Lymphovascular involvement; Maximum standardized uptake value; Pathological stage I lung adenocarcinoma; Prognostic factor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; AGED; CANCER STAGING; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; LYMPH VESSEL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903166668     PISSN: 13411098     EISSN: 21861005     Source Type: Journal    
DOI: 10.5761/atcs.oa.12.02219     Document Type: Article

References (15)

1. Alberg AJ, Ford JG, Samet JM, et al. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 29S-55S.
2. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12.
3. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.
4. Harpole DH, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51-6.
5. Rubins J, Unger M, Colice GL. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007; 132(3 Suppl): 355S-67S.
6. Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010; 5: 612-9.
7. Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008; 3: 130-4.
8. Murakami S, Saito H, Sakuma Y, et al. Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma. Eur J Radiol 2012; 81: 1891-5. [Epub ahead of print].
9. Ohtsuka T, Nomori H, Watanabe K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006; 107: 2468-73.
10. Shiono S, Abiko M, Okazaki T, et al. Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg 2011; 40: 1165-9.
11. Nair VS, Barnett PG, Ananth L, et al. PET scan 18Ffluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 2010; 137: 1150-6.
12. Downey RJ, Akhurst T, Gonen M, et al. Preoperative dF-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Onocol 2004; 22: 3255-60.
13. Vesselle H, Salskov A, Turcotte E, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008; 3: 971-8.
14. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41: 85-92.
15. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 2012; 19: 3598-605. [Epub ahead of print].